Quantitative Analysis of Proteins Related to Chemoresistance to Paclitaxel and Carboplatin in Human SiHa Cervical Cancer Cells Via ITRAQ

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2020 Jan 9

PMID 31912682

Citations 1

Authors

Yue He

Su Bin Han

Yu Ning Geng

Shu Li Yang

Yu Mei Wu

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to identify proteins related to paclitaxel and carboplatin chemoresistance in cervical cancer.

Methods: Quantitative proteomic analysis was performed on normal SiHa cells and those treated with paclitaxel and carboplatin for 14 days, with isobaric tags for relative and absolute quantitation (iTRAQ) analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to identify related processes and differentially expressed proteins.

Results: A total of 67 and 96 differentially expressed proteins were identified in the paclitaxel- and carboplatin- treated groups, respectively. GO and KEGG enrichment analyses identified 53 (43 upregulated and 10 downregulated) and 85 differentially expressed proteins (70 upregulated and 15 downregulated) in the paclitaxel- and carboplatin-treated groups, respectively. The cell counting kit-8 results revealed that APOA1 was overexpressed in both the paclitaxel- and carboplatin- resistant SiHa cells compared with the control cells. Immunohistochemistry showed that APOA1 was highly expressed in the paclitaxel- and carboplatin- resistant squamous cell carcinoma of the cervix.

Conclusion: This study is the first to use iTRAQ to identify paclitaxel- and carboplatin- resistance proteins in cervical cells. We identified several proteins previously unassociated with paclitaxel and carboplatin resistance in cervical cancer, thereby expanding our understanding of paclitaxel and carboplatin resistance mechanisms. Moreover, these findings indicate that the APOA1 protein could serve as a potential marker for monitoring and predicting paclitaxel and carboplatin resistance levels.

Citing Articles

Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer.

He Y, Han S, Liu Y, Zhang J, Wu Y BMC Cancer. 2022; 22(1):411.

PMID: 35421932 PMC: 9009492. DOI: 10.1186/s12885-022-09528-x.

References

McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs M, Symonds R, Warwick V . A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013; 108(12):2464-9. PMC: 3694233. DOI: 10.1038/bjc.2013.230. View

Cine N, Baykal A, Sunnetci D, Canturk Z, Serhatli M, Savli H . Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncol Rep. 2014; 32(3):1078-86. DOI: 10.3892/or.2014.3277. View

. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26(35):5802-12. PMC: 2645100. DOI: 10.1200/JCO.2008.16.4368. View

Yang Z, Chen D, Zhang J, Yao D, Gao K, Wang H . The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicenter study. Gynecol Oncol. 2015; 141(2):231-239. DOI: 10.1016/j.ygyno.2015.06.027. View

Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J . Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009; 200(6):639.e1-5. DOI: 10.1016/j.ajog.2008.12.042. View

Moore L, Fung E, McGuire M, Rabkin C, Molinaro A, Wang Z . Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1641-6. DOI: 10.1158/1055-9965.EPI-05-0980. View

Jahangiri A . High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes. 2010; 17(2):156-60. PMC: 2917341. DOI: 10.1097/MED.0b013e328337278b. View

Xie S, Li G, Qu L, Cao Y, Wang Q, Zhou J . Identification of New Epididymal Luminal Fluid Proteins Involved in Sperm Maturation in Infertile Rats Treated by Dutasteride Using iTRAQ. Molecules. 2016; 21(5). PMC: 6273551. DOI: 10.3390/molecules21050602. View

Wu W, Wang Q, Yin F, Yang Z, Zhang W, Gabra H . Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. Int J Oncol. 2016; 49(4):1651-65. DOI: 10.3892/ijo.2016.3652. View

10.

Lapresa M, Parma G, Portuesi R, Colombo N . Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015; 15(10):1171-81. DOI: 10.1586/14737140.2015.1079777. View

11.

Moore M, Attasara P, Khuhaprema T, Le T, Nguyen T, Raingsey P . Cancer epidemiology in mainland South-East Asia - past, present and future. Asian Pac J Cancer Prev. 2010; 11 Suppl 2:67-80. View

12.

Bencharif K, Hoareau L, Murumalla R, Tarnus E, Tallet F, Clerc R . Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids Health Dis. 2010; 9:75. PMC: 2917427. DOI: 10.1186/1476-511X-9-75. View

13.

Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W . A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br J Cancer. 2017; 117(12):1846-1854. PMC: 5729477. DOI: 10.1038/bjc.2017.365. View

14.

Wang Y, Wang G, Wei L, Huang L, Wang J, Wang S . Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement. Chin J Cancer. 2011; 30(9):645-54. PMC: 4013327. DOI: 10.5732/cjc.011.10050. View

15.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

16.

Zhang Z, Bulur P, Dogan A, Gastineau D, Dietz A, Lin Y . Immune independent crosstalk between lymphoma and myeloid suppressor CD14HLA-DR monocytes mediates chemotherapy resistance. Oncoimmunology. 2015; 4(4):e996470. PMC: 4485750. DOI: 10.1080/2162402X.2014.996470. View

17.

Panupinthu N, Lee H, Mills G . Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer. 2010; 102(6):941-6. PMC: 2844037. DOI: 10.1038/sj.bjc.6605588. View

18.

Lee Y, Ryu S, Bae S, Park T, Kwon K, Noh Y . Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer. Oncol Rep. 2015; 33(4):1985-93. DOI: 10.3892/or.2015.3810. View

19.

Lozano-Pope I, Sharma A, Matthias M, Doran K, Obonyo M . Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of Helicobacter-induced gastric cancer. BMC Cancer. 2017; 17(1):133. PMC: 5310019. DOI: 10.1186/s12885-017-3114-y. View

20.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View